- Home
- JBLU vs MIRM Comparison
JBLU vs MIRM Comparison
Compare JBLU & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBLU
- MIRM
- Stock Information
- Founded
- JBLU 1998
- MIRM 2018
- Country
- JBLU United States
- MIRM United States
- Employees
- JBLU N/A
- MIRM N/A
- Industry
- JBLU Air Freight/Delivery Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- JBLU Consumer Discretionary
- MIRM Health Care
- Exchange
- JBLU Nasdaq
- MIRM Nasdaq
- Market Cap
- JBLU 2.1B
- MIRM 2.0B
- IPO Year
- JBLU N/A
- MIRM 2019
- Fundamental
- Price
- JBLU $7.48
- MIRM $42.04
- Analyst Decision
- JBLU Sell
- MIRM Strong Buy
- Analyst Count
- JBLU 12
- MIRM 11
- Target Price
- JBLU $6.43
- MIRM $57.00
- AVG Volume (30 Days)
- JBLU 17.8M
- MIRM 376.0K
- Earning Date
- JBLU 01-28-2025
- MIRM 02-26-2025
- Dividend Yield
- JBLU N/A
- MIRM N/A
- EPS Growth
- JBLU N/A
- MIRM N/A
- EPS
- JBLU N/A
- MIRM N/A
- Revenue
- JBLU $9,327,000,000.00
- MIRM $307,028,000.00
- Revenue This Year
- JBLU N/A
- MIRM $82.14
- Revenue Next Year
- JBLU $4.99
- MIRM $26.18
- P/E Ratio
- JBLU N/A
- MIRM N/A
- Revenue Growth
- JBLU N/A
- MIRM 112.14
- 52 Week Low
- JBLU $4.50
- MIRM $23.14
- 52 Week High
- JBLU $8.28
- MIRM $48.89
- Technical
- Relative Strength Index (RSI)
- JBLU 55.64
- MIRM 47.79
- Support Level
- JBLU $7.67
- MIRM $40.91
- Resistance Level
- JBLU $8.28
- MIRM $42.40
- Average True Range (ATR)
- JBLU 0.39
- MIRM 1.45
- MACD
- JBLU 0.03
- MIRM -0.13
- Stochastic Oscillator
- JBLU 43.26
- MIRM 51.04
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The operating segments of company are Domestic & Canada, Caribbean & Latin America and Atlantic. Majority of revenue is generated from Domestic & Canada segment.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.